[Clinical studies on cefoperazone treatment for bile duct infections (author's transl)].
The clinical effects cefoperazone (CPZ) treatment for 10 patients with bile duct infection were investigated and the following results were obtained. 1. Absorption and excretion of CPZ: CPZ of 500 mg was administered with intravenous one shot injection to 2 patients of which one was malignant tumor case and the remaining was non tumor case. A peak of CPZ level in serum was 63.0 mcg/ml and 54.7 mcg/ml respectively. CPZ level in bile was maximum at 81.5 mcg/ml and 292.5 mcg/ml respectively. 2. Clinical effectiveness: Of 10 patients treated with CPZ, the results were excellent in 2 cases, good in 5 cases and poor in 3 cases. 3. Side effects of CPZ: No significant side effects were observed in these patients except for one case in which rash appeared in whole body.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D001649:Bile Duct Diseases / Q000188:drug therapy* / Q000382:microbiology; D002438:Cefoperazone; D002511:Cephalosporins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D002438:Cefoperazone